
Ascent Funding Student Loans: 2025 Review
Ascent Funding offers students the flexibility to apply with or without a cosigner, depending on their financial or academic profile. But it also offers flexible repayment plans, generous loan limits and cash back perks.
3.09% to 15.61% APR with autopay discount (undergraduate new loan). Other rates and loan types are available. Visit Ascent's website for full details.
Undergraduate and graduate loans, MBA, medical school, dental school, law school, doctorate and Master's, health professional loans.
$2,001 up to $200,000 for undergraduate loans and $400,000 for graduate loans
5, 7, 10, 12, 15, 20 years
Deferment and forbearance options available
For DACA recipients and non-U.S. citizens or permanent residents
No
Terms apply.
Ascent offers private student loans for students attending eligible undergraduate or graduate programs. If you're a graduate student, you can also apply for a cosigned credit-based loan if you have a creditworthy cosigner, such as a parent, guardian or sponsor, or a non-cosigned credit-based loan if you meet certain credit and income requirements on your own.
If you're enrolled in a specific type of graduate program, there are customized repayments terms available for:
Ascent also offers parent student loans for parents, grandparents, guardians or sponsors who want to help cover education costs, though eligibility requirements apply, as well as bootcamp loans, which are consumer loans designed for career-focused bootcamps or accelerated-learning programs.
Offers in this section are from affiliate partners and selected based on a combination of engagement, product relevance, compensation, and consistent availability.Undergraduate and graduate students, parents, health professionals$5,000 minimum (or up to state); maximum up to cost of attendance5, 7, 10, 15, years; up to 20 years for refinancing loans
Terms applyUndergraduate and graduate students, parents, international students with U.S. co-signer$1,000 up to the cost of attendance ($180,000 lifelong maximum)5, 8, 10, 15 years for undergraduate loans, up to 20 years for graduate loans
Terms apply
To qualify for an Ascent student loan, you must be enrolled at least half-time at an eligible institution. If you're applying for a non-cosigned outcomes-based loan, you must be a junior or senior enrolled full-time, or half-time within nine months of graduation at an eligible school.
If you're applying with a cosigner, your cosigner must have a minimum gross annual income of $24,000 for both the current and previous year. For the outcomes-based loan, you'll need to maintain a minimum GPA of 3.0 and meet your school's satisfactory academic progress standards.
Borrowers must be at least half-time in a degree program at an eligible U.S. college or university
Ascent doesn't publicly disclose specific credit score requirements but approval depends on several factors, including:
You can use Ascent's prequalification tool to get a better sense of which loan options you may be eligible for, without impacting your credit score.
The exact rates and terms of your Ascent loan may vary based on your credit and program.
Ascent offers fixed rates starting as low as 3.09% APR and variable rates starting at 4.31% APR.
Ascent offers loan terms of 5, 7, 10, 12, 15 or 20 years. There's no prepayment penalty so you can pay off your loan early without added fees.
If you select a 20-year term, you'll only be eligible for variable interest rates. And for loans with low balances, your minimum monthly payment account may shorten the total repayment period — meaning your loan may be paid off faster than the selected term.
Ascent does not charge any application, disbursement, prepayment or late fees.
The minimum loan amount available to borrowers is $2,001, while in Massachusetts it's $6,001. The maximum is $200,000 for undergraduate students, and $400,000 for graduate students.
Ascent offers a variety of repayment options based on your credit profile and whether you apply with or without a cosigner.
Interest-only: Pay only the interest while in school and during the grace period. Full payments begin after graduation.
$25 minimum: Make flat $25 monthly payments while in school. Full payments start after graduation.
Deferred: Make no payments while in school. Interest accrues and is added to the loan balance when repayment begins.
Other than not always needing a cosigner, Ascent offers a range of perks.
1% cash back reward: You can get 1% of your original loan amount back when you graduate, as long as you meet certain eligibility requirements.
Up to 1% interest rate discount: You can sign up for automatic payments to receive an interest rate reduction (0.25% for autopay, with additional promotional offers sometimes available).
High loan limits: You can borrow up to $200,000 for undergraduate loans, and up to $400,000 for graduate loans.
Ascent offers several advantages but there are some limitations to consider.
Ascent offers support via phone, email and live chat during business hours. It's generally well-rated for ease of application but customer service experiences can vary.
Applying for a student loan with Ascent is generally straightforward:
While Ascent offers flexible borrowing options, its interest rates can fall on the higher side, especially if you don't qualify for discounts. If low rates are your priority, Earnest offers some of the lowest starting APRs among private lenders. It also lets you pick your exact repayment timeline and doesn't charge late fees.
Undergraduate and graduate students, parents, half-time students, international and DACA students
Undergraduate, graduate loans, parent loans, MBA, medical school, law school, international and DACA student loans
$1,000 up to the cost of attendance for new loans, $5,000 to $550,000 for refinance loans
5, 7, 10, 12, 15 years
Nine-month grace period available
No
Yes - click here for details
Terms apply.If you're looking to refinance your student loans after graduation, SoFi is a top alternative. SoFi allows you to consolidate federal and private loans with no fees and potentially lower your interest rate, especially if your credit has improved or your income has increased.
3.23% to 15.99% APR with 0.25% autopay discount (Undergraduate New Loan). Other rates and loan types are available. Visit SoFi's website for full details.
Undergraduate, graduate, parent loans, law school, MBA and health professions loans
$5,000 (or state-mandated minimum) up to the cost of attendance
5, 7, 10, 15 years; refinancing loans up to 20 years
No
Yes - click here for details
Yes - click here for details
Terms apply.Money matters — so make the most of it. Get expert tips, strategies, news and everything else you need to maximize your money, right to your inbox. Sign up here.
At CNBC Select, our mission is to provide our readers with high-quality service journalism and comprehensive consumer advice so they can make informed decisions with their money. Every student loan review is based on rigorous reporting by our team of expert writers and editors with extensive knowledge of student loan products. While CNBC Select earns a commission from affiliate partners on many offers and links, we create all our content without input from our commercial team or any outside third parties, and we pride ourselves on our journalistic standards and ethics.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CNBC
17 minutes ago
- CNBC
AstraZeneca CEO doubles down on U.S. amid rumors of listing shift
AstraZeneca CEO Pascal Soriot on Tuesday reiterated the pharmaceutical firm's commitment to the U.S. market amid reports that he is considering shifting its listing stateside. Soriot said the U.K.-listed company had many reasons to be in the U.S., adding that it was "rapidly transferring manufacturing" across the Atlantic so it could serve all U.S. patient needs domestically. "We have lots of reasons to be here [in the U.S.]," Soriot told media during an earnings call. "This country [the U.S.] will represent, we hope, 50% of our revenue by 2030. We have thousands of employees … across the country," he added. AstraZeneca has been doubling down on the U.S. market, saying in its second-quarter earnings report on Tuesday that the country was key to its ambition of delivering $80 billion in revenue by the end of the decade. "We are a global company but we are certainly, very much, present and rooted in the U.S.," Soriot said, noting that it plans to soon become self-sufficient there. The company said last week it plans to invest $50 billion in bolstering its U.S. manufacturing and research capabilities. It marks the latest pharmaceutical firm to ramp up its stateside spending in the wake of U.S. trade tariffs and calls by President Donald Trump to reshore manufacturing. "Our investment is reflecting our belief in the growth of this country. We want to contribute to this," Soriot said, noting that he had met with the Trump administration to discuss growth plans within the sector. "The U.S. really leads in biopharmaceutical innovation these days," he added, criticizing Europe's failure to drive development. "Today, very little comes out of Europe." AstraZeneca, which made international headlines by developing one of the key Covid-19 vaccines, has long been prioritizing the U.S. market. The U.S. accounted for over 40% of the company's annual revenues in 2024. Earlier this month, The Times reported that the firm may move its listing from London to the U.S., in what analysts said would be a major blow to the U.K.'s public markets. AstraZeneca at the time declined to comment on the report. However, chief financial officer Aradhana Sarin said Tuesday that the company remains "committed" to the U.K. It comes as AstraZeneca posted better-than-expected second-quarter earnings on Tuesday, driven by demand for key cancer and biopharmaceutical products. The Anglo-Swedish pharma firm posted revenues of $14.46 billion over the three-month period to June 30, ahead of the $14.07 billion estimated by analysts in an LSEG poll. Quarterly adjusted core operating profit came in at $4.58 billion versus $4.48 billion anticipated. The FTSE 100 company maintained its full-year forecast for revenues to rise by a high single-digit percentage and core earnings per share to increase by a low double-digit percentage. It comes as the European pharmaceutical sector is facing anticipated levies of 15% on imports to the U.S. as part of a broader EU-U.S. trade deal. Analysts warned that the tariffs, if levied at 15% or above, could hamper European firms and the bloc's broader economy. AstraZeneca nevertheless suggested in April that it would maintain its 2025 sales guidance if U.S. tariffs on European pharma products came in in line with those levied against other sectors. "This issue of tariffs is not really an issue that is affecting us very much," Soriot said.


CBS News
an hour ago
- CBS News
Stellantis warns of $1.7 billion earnings hit from tariffs
Stellantis, the maker of more than a dozen automotive brands, on Tuesday said that President Trump's tariffs will cost the auto manufacturer 1.5 billion euros, or about $1.7 billion, in 2025. The parent company of brands like Chrysler, Fiat, Jeep and Peugeot announced the projected earnings hit as Mr. Trump clinches deals with U.S. trade partners that include steep tariffs on U.S. imports, ahead of an Aug. 1 deadline. Stellantis said it expects the majority of the hit, about 1.2 billion euros, will come in the second half of 2025. "Stellantis updates its estimate of 2025 net tariff impact to approximately €1.5 billion, of which €0.3 billion was incurred in H1 2025. The Company remains highly engaged with relevant policymakers, while continuing long-term scenario planning," the company said in a statement Tuesday as it reported financial results for the first half of 2025. The automaker acknowledged that Mr. Trump's 25% tariffs on imports of autos and auto parts to the U.S. are hurting its business, particularly in North America. Stellantis builds its Chrysler, Dodge and Jeep brand vehicles in factories in Canada and Mexico, meaning they're subject to the new levies. While Mr. Trump's deal with the EU, calling for 15% tariffs across the board will make BMW and Mercedes-Benz vehicles more expensive for U.S. consumers, according to analysts. Stellantis is largely unaffected by the EU agreement. "Stellantis isn't much affected by the EU/US tariff news — the question for STLA is if the Detroit-3 will want to renegotiate the [U.S.-Mexico-Canada Agreement (USMCA)] tariff after the EU and Japan got a better deal," UBS analysts said in a research note. Other automobile manufacturers, including General Motors, have been bracing for impact from tariffs. GM CEO Mary Barra said the company took a $1.1 billion hit from tariffs in the second quarter, and that the company is taking steps to reduce its tariff exposure by investing in U.S. assembly plants. European automaker Volkswagen also said last week that tariffs cost the company $1.5 billion in the first half of 2025.


CNBC
an hour ago
- CNBC
AI and technology will continue to be the dominant theme for investors throughout the year: JPMorgan
Grace Peters, Co-Head of Global Investment Strategy at JPMorgan Private Bank, discusses what investors should be watching out for and the impact of the EU-U.S. trade agreement on global markets